RxDoctor Payments Data

Michelle Bear, DO

Family Medicine · Bridgeton, NJNPI 1508894494

Payments from drug & device makers

$6,560in general payments, 2019–2025

Across 506 payments — averaging $12.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$902
  • Pfizer$551
  • AstraZeneca$538
  • AbbVie$436
  • Lilly USA, LLC$420
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,552100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,560 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,073
Medicare patients
268
Services billed
1,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$96,049
JardianceEmpagliflozin45$64,034
JanuviaSitagliptin Phosphate29$36,714
TrulicityDulaglutide20$29,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,612
Tresiba Flextouch U-100Insulin Degludec15$7,676
Tresiba Flextouch U-200Insulin Degludec14$6,525
Verapamil Er PmVerapamil Hcl14$4,657
Atorvastatin Calcium337$4,024
Albuterol Sulfate HfaAlbuterol Sulfate73$2,667
Metoprolol Succinate138$2,446
Levothyroxine Sodium166$2,359
Raloxifene Hcl21$2,254
Amlodipine Besylate210$2,002
Lisinopril177$1,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,648$96,04959 claims
Boehringer IngelheimJardiance$282$64,03445 claims
MerckJanuvia$166$36,71429 claims
Lilly USA, LLCTrulicity$420$29,53820 claims
GSKTrelegy Ellipta$902$18,61228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Bridgeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →